RxDoctor Payments DataLook up a doctor →

Bogdan Gheorghiu, MD

Neurology · Spartanburg, SCNPI 1902892904

Payments from drug & device makers

$105,507in general payments, 2019–2025

Across 1,286 payments — averaging $82.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$64K
  • Avanir Pharmaceuticals, Inc.$13K
  • AbbVie$4K
  • Biogen$4K
  • Acadia Pharmaceuticals Inc$4K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $15K from 54 others
$6,901in research payments, 2019–2025

Across 3 payments — averaging $2300.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$6K
  • AbbVie$476

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$1431%
  • Food & beverage$22,24796%
  • Education$4712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis87$63,959
Avanir Pharmaceuticals, Inc.20$13,459
AbbVie(2 entities)148$4,071
Biogen96$3,932
Acadia Pharmaceuticals Inc86$3,734
Teva Pharmaceuticals USA, Inc.88$1,454
EMD Serono, Inc.44$1,083
Neurocrine Biosciences, Inc.44$852
Lilly USA, LLC46$793
UCB, Inc.41$783
Supernus Pharmaceuticals, Inc.57$778
Amgen(2 entities)35$702
Lundbeck LLC30$650
Eisai Inc.31$624
AstraZeneca(2 entities)31$620
Sanofi26$574
Pfizer35$535
MDD US Operations, LLC18$396
Argenx US, Inc.16$377
Bristol Myers Squibb19$364
Sunovion Pharmaceuticals Inc.17$346
Mallinckrodt Hospital Products Inc.15$332
Acorda Therapeutics, Inc14$319
Amneal Pharmaceuticals LLC16$306
Kyowa Kirin, Inc.14$277
Takeda Pharmaceuticals U.S.A., Inc.11$274
Otsuka America Pharmaceutical, Inc.11$245
Bausch Health US, LLC16$242
Merz Pharmaceuticals, LLC8$218
Biohaven Pharmaceutical Holding Company Ltd.11$217
Tanabe Pharma America, Inc.11$204
Genentech USA, Inc.12$194
SK Life Science, Inc.10$194
Biohaven Pharmaceuticals, Inc.9$189
Impel Pharmaceuticals Inc.16$185
TG Therapeutics, Inc.7$153
Upsher-smith Laboratories LLC8$152
Grifols USA, LLC8$150
Livanova USA, Inc.6$142
Johnson & Johnson7$140
Neurelis, Inc.7$137
Mallinckrodt Enterprises LLC5$103
Dynasplint Systems Inc.1$103
ANI Pharmaceuticals, Inc.4$99
Catalyst Pharmaceuticals, Inc.3$72
Harmony Biosciences LLC4$71
Octapharma USA, Inc.1$67
E.r. Squibb & Sons, L.L.C.4$65
Adamas Pharmaceuticals, Inc.4$59
Vanda Pharmaceuticals Inc.3$54
Aprecia Pharmaceuticals, LLC3$52
Sandoz2$48
Scilex Pharmaceuticals Inc.3$44
Alnylam Pharmaceuticals Inc.2$43
Axsome Therapeutics, Inc.2$40
Banner Life Sciences, LLC2$35
Cycle Pharmaceuticals Inc2$34
Abbott2$28
CSL Behring1$25
Sanofi-aventis U.S. LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,507 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$307,908
Medicare patients
854
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone11$357,657
Gamunex-CImmune Globul G/Gly/Iga Avg 4617$98,114
CopaxoneGlatiramer Acetate12$69,984
Aimovig AutoinjectorErenumab-Aooe35$24,934
Emgality PenGalcanezumab-Gnlm16$19,160
EliquisApixaban21$16,518
Nurtec OdtRimegepant Sulfate14$15,764
VimpatLacosamide12$13,020
NamzaricMemantine Hcl/Donepezil Hcl17$9,735
Lacosamide78$7,753
Pregabalin243$6,813
Levetiracetam178$6,152
Memantine Hcl400$5,958
Memantine Hcl ErMemantine Hcl70$5,382
Carbidopa-Levodopa ErCarbidopa/Levodopa77$5,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$3,932$357,65711 claims
Grifols USA, LLCGamunex-C$150$98,11417 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,454$69,98412 claims
PfizerEliquis, Nurtec Odt$535$32,28235 claims
UCB, Inc.Vimpat$783$13,02012 claims
AbbVieNamzaric$4,071$9,73517 claims
Upsher-smith Laboratories LLCTopiramate$152$2,236250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.

Other neurology in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →